RTTNews | Jan 6, 2022 10:10AM EST

10:09 Thursday, January 6, 2022 (RTTNews.com) - Shares of molecular genetics diagnostic company Mainz Biomed B.V. (MYNZ) are down 5 percent on Thursday's trading, thus breaking the stock's upward movement since Wednesday after the company announced that it had acquired exclusive rights to novel mRNA biomarkers.

Mainz Biomed had entered into a Technology Rights Agreement with Socpra Sciences Sant Et Humaines S.E.C. to access a portfolio of novel mRNA biomarkers for potential future integration into ColoAlert, the company's easy-to-use detection test for colorectal cancer. Currently at $13.85, the stock has traded between $7.80 and $18.68 during the past 52 weeks.

Read the original article on RTTNews ( https://www.rttnews.com/3253279/mainz-biomed-shares-down-5-reversing-uptrend.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2022 RTTNews.com All Rights Reserved